izalontamab brengitecan + osimertinib

izalontamab brengitecan + osimertinib is an investigational combination therapy being evaluated for advanced non-small cell lung cancer (NSCLC) in patients harboring EGFR mutations who have progressed after EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy[1][3][4]. - **Izalontamab brengitecan** is a bispecific antibody-drug conjugate (ADC) designed to simultaneously target Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 3 (HER3). Upon binding, it delivers a DNA topoisomerase I inhibitor payload that damages cancer cell DNA and induces cell death[1][3][7]. - **Osimertinib** is a third-generation EGFR tyrosine kinase inhibitor that selectively inhibits both EGFR-sensitizing and T790M resistance mutations. The combination aims to provide a more comprehensive blockade of EGFR signaling with direct inhibition (osimertinib) plus receptor targeting and cytotoxic payload delivery (izalontamab brengitecan), particularly for patients who have developed resistance to prior EGFR-targeted therapy.

Brand names

Tagrisso

Other names

izalontamab brengitecan + osimertinib